Scale, breadth and depth of services will always be key drivers for pharmaceutical outsourcing, and CDMOs that can offer a wide range of technologies and expertise are uniquely placed to act as a one-stop-shop partner.

There needs to be some strategy behind the merger and acquisition (M&A) activity. It must fulfil a need.

With this in mind, consolidation is prominent within the pharmaceutical industry with larger CDMOs looking to expand their offering and achieve strategic growth through acquisitions.

Our Executive Vice President – Corporate Development, Mark Quick, discusses the importance of making informed decisions when it comes to mergers and acquisitions with Pharmaceutical Technology.

Read the full article here

PharmTech, Feb 23, 2017